High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-b-type natriuretic peptide

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 11, 2011, Pages 1899-1906

  Jungbauer, Carsten G ^a   Riedlinger, Julia ^b   Buchner, Stefan ^a   Birner, Christoph ^a   Resch, Markus ^a   Lubnow, Matthias ^a   Debl, Kurt ^a   Buesing, Monika ^a   Huedig, Hendrik ^b   Riegger, Günter ^a   Luchner, Andreas ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Cardiac markers; Chronic heart failure; High sensitive troponin T; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN T;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; GERMANY; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TROPONIN T; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80755171218     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.251     Document Type: Article

References (33)

1. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9. (Pubitemid 26360452)
2. Donnelly R, Millar-Craig MW. Cardiac troponins: IT upgrade for the heart. Lancet 1998;351:537-9. (Pubitemid 28077554)
3. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, for the FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-47.
4. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med 2002;346:2047-52. (Pubitemid 34680596)
5. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.
6. Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999;84:608-11. (Pubitemid 29408600)
7. Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002;89: 691-5. (Pubitemid 34230565)
8. Bertinchant JP, Combes N, Polge A, Fabbro-Peray P, Raczka F, Beck L, et al. Prognostic value of cardiac troponin T in patients with both acute and chronic stable congestive heart failure: comparison with atrial natriuretic peptide, brain natriuretic peptide and plasma norepinephrine. Clin Chim Acta 2005;352: 143-53. (Pubitemid 40093866)
9. Healey JS, Davies RF, Smith SJ, Davies RA, Ooi DS. Prognostic use of cardiac troponin T and troponin I in patients with heart failure. Can J Cardiol 2003;19:383-6. (Pubitemid 36603504)
10. Katus HA, Giannitsis E, Jaffe AS, Thygesen K. Higher sensitivity troponin assays: quo vadis? Eur Heart J 2009;30:127-8.
11. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/ WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
12. Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009; 55:101-8.
13. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, et al. Val-HeFT investigators. prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-9.
14. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10: 933-89.
15. Koerbin G, Tate JR, Hickman PE. Analytical characteristics of the Roche highly sensitive troponin T assay and its application to a cardio-healthy population. Ann Clin Biochem 2010;47: 524-8.
16. Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 2004;42:965-72.
17. Bertsch T, Braun SL, Giannitsis E, Knebel F, Weber M, Christ M. Conference on clinical use of troponin T high sensitive (TnThs) on September 8, 2009 at the airport conference center, Frankfurt/ Main. Clin Lab 2010;56:355-8.
18. Chen AA, Wood MJ, Krauser DG, Baggish AL, Tung R, Anwaruddin S, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the proBNP Investigation of Dyspnea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 2006;27: 839-45.
19. Jungbauer CG, Buchner S, Birner C, Resch M, Heinicke N, Debl K, et al. N-terminal pro-brain natriuretic peptide from fresh urine for the biochemical detection of heart failure and left ventricular dysfunction. Eur J Heart Fail 2010;12:331-7.
20. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006;113: 1958-65.
21. Clerico A, Fortunato A, Ripoli A, Prontera C, Zucchelli GC, Emdin M. Distribution of plasma cardiac troponin I in healthy subjects: pathophysiological considerations. Clin Chem Lab Med 2008;46:804-8. (Pubitemid 351821637)
22. Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiactroponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009;54: 1165-72.
23. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:1-82.
24. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348: 2007-18.
25. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47:287-96. (Pubitemid 27395959)
26. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004;43:416-22. (Pubitemid 38167702)
27. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide (BNP) as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertension 2000;18:1121-8.
28. Luchner A, Hengstenberg C, Löwel H, Trawinski J, Baumann M, Riegger GA, et al. Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients after myocardial infarction: a biochemical marker of cardio-renal function. Hypertension 2002;39:99-104. (Pubitemid 34098096)
29. Luchner A, Hengstenberg C, Löwel H, Buchner S, Schunkert H, Riegger GA, et al. NT-proBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. J Cardiac Fail 2005;11(Suppl 5):S21-7.
30. Masson S, Latini R, Anand IS. An update on cardiac troponins as circulating biomarkers in heart failure. Curr Heart Fail Rep 2010;7:15-21.
31. Capasso JM, Malhotra A, Li P, Zhang X, Scheuer J, Anversa P. Chronic non-occlusive coronary artery constriction impairs ventricular function, myocardial structure, and cardiac contractile protein enzyme activity in rats. Circ Res 1992;70:148-62.
32. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
33. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 1999;96:8144-9. (Pubitemid 29328422)